Expression of p53 and p21(wafl/cip1) in gastric carcinoma: Lack of inter-relationship or correlation with prognosis

European Journal of Surgical Oncology

Volumn 26, Issue 1, 2000, Pages 39-43

  Kaye, P V ^a   Radebold, K ^a   Isaacs, S ^a   Dent, D M ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Cell cycle regulators; Gastric carcinoma; Immunohistochemistry; Prognosis

Indexed keywords

PROTEIN P21; PROTEIN P53; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; TUMOR MARKER;

ADULT; ARTICLE; CANCER SURVIVAL; CLINICAL FEATURE; DIAGNOSTIC VALUE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SEX DIFFERENCE; STOMACH CARCINOMA; CANCER STAGING; CHEMISTRY; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; MALE; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; STOMACH TUMOR; SURVIVAL;

CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033621762     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejso.1999.0738     Document Type: Article

References (28)

1. Nakamura K, Ueyama T, Yao T. Pathology and prognosis of gastric carcinoma. Cancer. 70:1997;1030-1037.
2. Chang F, Syrjanen S, Tervahanta A, Syrjanen K. Tumorigenesis associated with the p53 tumour suppressor gene. Br J Cancer. 68:1993;653-661.
3. Jacks T, Weinberg RA. Cell-cycle control and its watchman. Nature. 381:1996;643-644.
4. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature. 351:1991;453-456.
5. Baas IO, Mulder J-WR, Offerhaus JA, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol. 172:1994;5-12.
6. Hall PA, Lane DP. p53 in tumour pathology: can we trust immunohistochemistry? - revisited. J Pathol. 172:1994;1-4.
7. Bukholm IK, Nesland JM, Karesen R, Jacobsen U, Borresen AL. Relationship between abnormal p53 protein and failure to express p21 protein in human breast carcinomas. J Pathol. 181:1997;140-145.
8. WAF1immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. Br J Cancer. 74:1996;208-215.
9. Wakasugi E, Kobayashi T, Tamaki Y. p21(Waf1/Cip1) and p53 protein expression in breast cancer. Am J Clin Pathol. 107:1997;684-691.
10. Martin HM, Filipe MI, Morris RW, Lane DP, Silvestre F. p53 expression and prognosis in gastric carcinoma. Int J Cancer. 50:1992;859-862.
11. Kakeji Y, Korenaga D, Tsujitani S. Gastric cancer with p53 overexpression has high potential for metastasizing to lymph nodes. Br J Cancer. 67:1993;589-593.
12. Joypaul BV, Hopwood D, Newman EL. The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma. Br J Cancer. 69:1994;943-946.
13. Hurlimann J, Saraga EP. Expression of p53 protein in gastric carcinomas. Am J Surg Path. 18:1994;1247-1253.
14. Schneider BG, Hilsenbeck SG, Hensel CH. p53 mutations in gastric and colorectal cancers in Texas Hispanics versus Anglos. Virchows Archiv. 424:1994;187-193.
15. Motojima K, Furui J, Kohara N, Ito T, Kanematsu T. Expression of p53 protein in gastric carcinomas is not independently prognostic. Surgery. 116:1994;890-895.
16. Gabbert HE, Muller W, Schneiders A, Meier S, Hommel G. The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer. 76:1995;720-726.
17. Victorzon M, Nordling S, Haglund C, Lundin J, Roberts PJ. Expression of p53 protein as a prognostic factor in patients with gastric cancer. Eur J Cancer. 32A:1996a;215-220.
18. Lim BHG, Soong R, Grieu F. p53 accumulation and mutation are prognostic indicators of poor survival in human gastric carcinoma. Int J Cancer. 69:1996;200-204.
19. Starzynska T, Markiewski M, Domagala W. The clinical significance of p53 accumulation in gastric carcinoma. Cancer. 77:1996;2005-2011.
20. Gomyo Y, Ikeda M, Osaki M. Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer. 79:1997;2067-2072.
21. Lambkin HA, Mothersill CM, Kelehan P. Variations in immunohistochemical detection of p53 protein overexpression in cervical carcinomas with different antibodies and methods of detection. J Pathol. 172:1994;13-18.
22. Digiuseppe JA, Redston MS, Yeo CJ, Kern SE, Hruban RH. p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol. 147:1995;884-888.
23. Diab SG, Yu YY, Hilsenbeck SG, Allred DC, Elledge RM. WAF1/CIP1 protein expression in human breast tumours. Breast Cancer Res Treat. 43:1997;99-103.
24. waf1/cip1expression correlates with disease progression in gastric carcinoma. Br J Cancer. 75:1997;1617-1620.
25. Moskaluk CA, Heitmiller R, Zahurak M. p53 and p21(WAF1/CIP1/SDI1) gene products in Barrett esophagus and adenocarcinoma of the esophagus and esophagogastric junction. Hum Pathol. 27:1996;1211-1220.
26. Solcia E, Fiocca R, Luinetti O. Intestinal and diffuse gastric cancers arise in a different background of helicobacter pylori gastritis through different gene involvement. Am J Surg Pathol. 20:1996;S8-S22.
27. Maehara Y, Sakaguchi Y, Moriguchi S. Signet ring carcinoma of the stomach. Cancer. 69:1992;1645-1650.
28. Otsuji E, Yamaguchi T, Sawai K, Takahashi T. Characterization of signet ring carcinoma of the stomach. J Surg Oncol. 67:1998;216-220.